Author:
Rass K.,Diefenbacher M.,Tilgen W.
Publisher
Springer Science and Business Media LLC
Reference38 articles.
1. Agarwala SS, Keilholz U, Hogg D et al. (2007) Randomized phase III study of paclitaxel plus carboplatin with or without sorafenib as second-line treatment in patients with advanced melanoma. J Clin Oncol ASCO Annual Meeting Proceedings 25: 8510 (Abstract)
2. Balch CM, Soong SJ, Gerschenwald JE et al. (2001) Prognostic factors analysis of 17.600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 19: 3622–3634
3. Bayes M, Rabasseda X, Prous JR (2004) Gateways to clinical trials. Meth Find Exp Clin Pharmacol 26: 473–503
4. Becker JC, Kirkwood JM, Agarwala SS et al. (2006) Molecular targeted therapy for melanoma – current reality and future options. Cancer 107: 2317–2327
5. Bedikian AY, Millward M, Pehamberger H et al. (2006) Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: The Oblimersen Melanoma Study Group. J Clin Oncol 24: 4738–4745
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Chemotherapy for Melanoma;Diagnostic and Prognostic Biomarkers and Therapeutic Targets in Melanoma;2011-11-18
2. Palliative Therapie des malignen Melanoms im Stadium IV;Der Onkologe;2009-07-29